- Home
- AUDC vs DBVT Comparison
AUDC vs DBVT Comparison
Compare AUDC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- DBVT
- Stock Information
- Founded
- AUDC 1992
- DBVT 2002
- Country
- AUDC Israel
- DBVT France
- Employees
- AUDC N/A
- DBVT N/A
- Industry
- AUDC Telecommunications Equipment
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AUDC Utilities
- DBVT Health Care
- Exchange
- AUDC Nasdaq
- DBVT Nasdaq
- Market Cap
- AUDC 279.1M
- DBVT 237.4M
- IPO Year
- AUDC 1999
- DBVT N/A
- Fundamental
- Price
- AUDC $9.44
- DBVT $9.40
- Analyst Decision
- AUDC Buy
- DBVT Buy
- Analyst Count
- AUDC 3
- DBVT 4
- Target Price
- AUDC $11.67
- DBVT $14.81
- AVG Volume (30 Days)
- AUDC 46.4K
- DBVT 41.9K
- Earning Date
- AUDC 07-29-2025
- DBVT 07-29-2025
- Dividend Yield
- AUDC 1.90%
- DBVT N/A
- EPS Growth
- AUDC 57.57
- DBVT N/A
- EPS
- AUDC 0.56
- DBVT N/A
- Revenue
- AUDC $242,474,000.00
- DBVT $3,497,000.00
- Revenue This Year
- AUDC $1.54
- DBVT $1,700.53
- Revenue Next Year
- AUDC $1.41
- DBVT $535.67
- P/E Ratio
- AUDC $16.86
- DBVT N/A
- Revenue Growth
- AUDC N/A
- DBVT N/A
- 52 Week Low
- AUDC $7.70
- DBVT $2.21
- 52 Week High
- AUDC $12.72
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- AUDC 54.43
- DBVT 52.73
- Support Level
- AUDC $9.06
- DBVT $9.00
- Resistance Level
- AUDC $9.54
- DBVT $10.12
- Average True Range (ATR)
- AUDC 0.20
- DBVT 0.57
- MACD
- AUDC -0.00
- DBVT 0.08
- Stochastic Oscillator
- AUDC 67.02
- DBVT 72.24
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.